Published in J Am Soc Nephrol on August 20, 2015
IL-21 Receptor Antagonist Inhibits Differentiation of B Cells toward Plasmablasts upon Alloantigen Stimulation. Front Immunol (2017) 1.38
Approach to the Highly Sensitized Kidney Transplant Candidate. Clin J Am Soc Nephrol (2016) 0.89
Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol (2016) 0.85
Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol (2016) 0.79
The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant (2016) 0.78
Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation. Front Immunol (2016) 0.78
Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor-Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching. Am J Transplant (2016) 0.77
The Complement System and Antibody-Mediated Transplant Rejection. J Immunol (2015) 0.76
Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes? J Immunol Res (2017) 0.76
Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein. Sci Rep (2016) 0.75
B Cell Immunity in Solid Organ Transplantation. Front Immunol (2017) 0.75
The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies. J Immunol Res (2016) 0.75
Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells. Kidney Int (2016) 0.75
IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES. Trans Am Clin Climatol Assoc (2016) 0.75
Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients. J Am Soc Nephrol (2015) 0.75
Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians. Transplantation (2016) 0.75
From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. J Immunol Res (2017) 0.75
Current status of alloimmunity. Curr Opin Nephrol Hypertens (2016) 0.75
Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection. J Immunol Res (2017) 0.75
Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. J Am Soc Nephrol (2016) 0.75
Moving Biomarkers toward Clinical Implementation in Kidney Transplantation. J Am Soc Nephrol (2017) 0.75
Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. Pediatr Nephrol (2017) 0.75
Kidney Transplant with Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly-Sensitized Transplant Candidates. Transplantation (2016) 0.75
Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. PLoS One (2017) 0.75
Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans. Transplantation (2017) 0.75
The exciting "bench to bedside" journey of cell therapies for acute kidney injury and renal transplantation. J Nephrol (2017) 0.75
Complement Recognition Pathways in Renal Transplantation. J Am Soc Nephrol (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Rejection of the kidney allograft. N Engl J Med (2010) 3.30
IgG4-related disease. Lancet (2014) 3.04
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet (2004) 2.82
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant (2014) 2.01
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2004) 1.91
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int (1997) 1.72
NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 1.62
Determinants of C1q binding in the single antigen bead assay. Transplantation (2014) 1.51
Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int (2013) 1.50
IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis (1994) 1.46
C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation (2011) 1.43
Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol (2011) 1.40
The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol (2012) 1.29
Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant (2004) 1.14
Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis. Clin Immunol Immunopathol (1988) 1.10
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl (2012) 1.10
Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation (2011) 1.03
The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res (2007) 1.01
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol (2015) 1.00
Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant (2011) 0.99
Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc (2013) 0.95
Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation (2007) 0.93
IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2002) 0.92
Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation (2014) 0.91
Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation (2013) 0.88
Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation (2004) 0.88
Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation (2004) 0.86
Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol (2013) 0.85
B cells take their time: sequential IgG class switching over the course of an immune response? Immunol Cell Biol (2014) 0.84
Immunoglobulin-G subclass antidonor reactivity in transplant recipients. Liver Transpl (2004) 0.81
Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J Am Soc Nephrol (2006) 0.80
Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol (2010) 0.80
The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation (1992) 0.80
Pretransplant rejection risk assessment through enzyme-linked immunosorbent assay analysis of anti-HLA class I antibodies. Am J Kidney Dis (1996) 0.79
Association of IgG immunoglobulin and subclasses level with the severity of chromoblastomycosis due to Fonsecaea pedrosoi and therapeutic response to itraconazole. Eur J Clin Microbiol Infect Dis (2014) 0.79
Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol (2004) 0.78
The complexity of the humoral immune response against HLA antigens. Transpl Int (2014) 0.78
Pretransplant and posttransplant monitoring of anti-HLA class I IgG1 antibodies by ELISA identifies patients at high risk of graft loss. Transplant Proc (1997) 0.77